Philippe Pinton

ORCID: 0000-0002-4227-7687 · 3 papers in corpus
rct 2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2025.113946

BACKGROUND: This study evaluated the effectiveness of quinagolide vaginal ring on reducing total lesion size in endometrioma, deep infiltrating endometriosis (DIE), and adenomyosis, as assessed using high-resolution MRI and imaging biomarke…

2024
BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deae092

Study questionHow does a gonadotrophin-releasing hormone (GnRH) agonist versus a GnRH antagonist protocol affect ovarian response when using an individualized fixed daily dose of follitropin delta for ovarian stimulation?Summary answerThe B…

article 2024
O-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results
·doi:10.1093/humrep/deae108.021

Abstract Study question Can MRI provide a useful assessment of changes to endometrioma, DIE, and adenomyosis lesion burden resulting from QVR treatment? Summary answer MRI successfully measured changes in the number, size, diffusion, and pe…